Your institution may have access to this item. Find your institution then sign in to continue.
Title
Biogen Idec bets on chronic pain.
Abstract
The article reports on the acquisition of the company Convergence Pharmaceuticals by the biotechnology firm Biogen Idec for 200 million U.S. dollars in upfront and up to 475 million U.S. dollars in milestone fees in order to expand its expand its neuropathic pain portfolio.